Article Text

Download PDFPDF

1205 Selective blockade of CD47-SIRP alpha “don’t eat me” signaling with a Her2-CD47 bispecific antibody-derivative
  1. Yuzhu Qi,
  2. Harm Lourens,
  3. Gerwin Huls and
  4. Edwin Bremer
  1. University Medical Center Groningen, Groningen, Netherlands


Background Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for ~25% of breast cancer cases. Trastuzumab improves clinical outcomes by targeting HER2, but recurrences still occur. Targeting the CD47-SIRPα interaction alone or in combination with therapeutic antibodies such as Trastuzumab contributes to cancer cell elimination, but ubiquitous CD47 blocking associates with toxicity. Here, we designed a bispecific antibody fragment aimed to selectively block CD47 on HER2-positive breast cancer cells (BC) in order to reduce off-tumor binding and limit toxicity towards normal CD47-positive cells, while increasing efficacy against cancer cells.

Methods A novel HER2-CD47 bispecific single chain fragment (HER2-CD47 bs-scFv) antibody with HA tag was produced in HEK293 cells and purified using Anti-HA affinity purification. The HER2-CD47 bs-scFv comprised a CD47-targeting scFv and a Her2-targeting trastuzumab-derived scFv fragment. For binding experiments, BC cells were incubated with HER2-CD47 bsAb in the presence (or absence) of either trastuzumab or anti-CD47 or both, whereupon binding was detected using anti-HA staining. Her-2 restricted blocking activity of the HER2-CD47 bs-scFv was assessed using recombinant human SIRP-α-Fc. For phagocytosis experiments, cancer cells were labelled with CSFE and then incubated with differentiated macrophages (derived from peripheral blood mononuclear cells). Phagocytosis was measured by flow cytometry.

Results The HER2-CD47 bispecific selectively bound to CD47+/Her2+ cells, but only marginally to single CD47 positive cancer cells. Binding of the HER2-CD47 bs-scFvwas partially reduced by trastuzumab or epitope-competing CD47 antibody. Furthermore, incubation with HER2-CD47 blocked the binding of recombinant human SIRPalpha-Fc only on CD47+/Her2+ cells, demonstrating that functional blocking of SIRP-alpha/CD47 interaction is restricted to HER2+ cells. Importantly, HER2-CD47 selectively enhanced macrophage-mediated phagocytic removal of CD47+/Her2+ BC cells cancer cells by up to 30%. In contrast, similar treatment did not significantly increase phagocytosis of CD47+/Her2- BC cells.

Conclusions The HER2-CD47 bs-scFv blocked CD47 “don’t eat me” signaling in a HER2-restricted manner with essentially only activity towards Her2 and CD47 double-positive cancer cells. This HER2-CD47 bs-scFv may provide a new strategy for the treatment of Her2+ breast cancers.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.